162 related articles for article (PubMed ID: 27528454)
1. The appropriateness and persistence of testosterone replacement therapy in Ontario.
Martins D; Yao Z; Tadrous M; Shah BR; Juurlink DN; Mamdani MM; Gomes T;
Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):119-126. PubMed ID: 27528454
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment patterns of testosterone replacement medications.
Donatucci C; Cui Z; Fang Y; Muram D
J Sex Med; 2014 Aug; 11(8):2092-9. PubMed ID: 24909541
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing patient decisions to initiate and discontinue subcutaneous testosterone pellets (Testopel) for treatment of hypogonadism.
Smith RP; Khanna A; Coward RM; Rajanahally S; Kovac JR; Gonzales MA; Lipshultz LI
J Sex Med; 2013 Sep; 10(9):2326-33. PubMed ID: 23859250
[TBL] [Abstract][Full Text] [Related]
4. Variations in costs and use of provincially-funded testosterone replacement therapy across Canada: a population-based study.
Tadrous M; Martins D; Lee K; Knowles S; Mamdani MM; Juurlink DN; Gomes T
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):803-807. PubMed ID: 26986676
[TBL] [Abstract][Full Text] [Related]
5. Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis.
Schoenfeld MJ; Shortridge E; Cui Z; Muram D
J Sex Med; 2013 May; 10(5):1401-9. PubMed ID: 23464534
[TBL] [Abstract][Full Text] [Related]
6. The impact of drug reimbursement policy on rates of testosterone replacement therapy among older men.
Piszczek J; Mamdani M; Antoniou T; Juurlink DN; Gomes T
PLoS One; 2014; 9(7):e98003. PubMed ID: 25029014
[TBL] [Abstract][Full Text] [Related]
7. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
8. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men.
Yassin A; Almehmadi Y; Saad F; Doros G; Gooren L
Clin Endocrinol (Oxf); 2016 Jan; 84(1):107-14. PubMed ID: 26331709
[TBL] [Abstract][Full Text] [Related]
9. Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men.
Borst SE; Yarrow JF
Am J Physiol Endocrinol Metab; 2015 Jun; 308(12):E1035-42. PubMed ID: 25898953
[TBL] [Abstract][Full Text] [Related]
10. Retrospective Analysis of Dose Titration and Serum Testosterone Level Assessments in Patients Treated With Topical Testosterone.
Muram D; Kaltenboeck A; Boytsov N; Hayes-Larson E; Ivanova J; Birnbaum HG; Swindle R
Am J Mens Health; 2015 Nov; 9(6):496-505. PubMed ID: 25271142
[TBL] [Abstract][Full Text] [Related]
11. Testosterone prescribing in men with depression and anxiety disorders.
Javed Z; Kuo YF; Temple JR; Urban RJ; Holmes H; Baillargeon J
Ann Epidemiol; 2020 Oct; 50():15-19.e8. PubMed ID: 32800673
[TBL] [Abstract][Full Text] [Related]
12. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
13. Patient satisfaction with testosterone replacement therapies: the reasons behind the choices.
Kovac JR; Rajanahally S; Smith RP; Coward RM; Lamb DJ; Lipshultz LI
J Sex Med; 2014 Feb; 11(2):553-62. PubMed ID: 24344902
[TBL] [Abstract][Full Text] [Related]
14. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations.
Giagulli VA; Triggiani V; Corona G; Carbone D; Licchelli B; Tafaro E; Resta F; Sabbà C; Maggi M; Guastamacchia E
Curr Pharm Des; 2011; 17(15):1500-11. PubMed ID: 21521164
[TBL] [Abstract][Full Text] [Related]
15. Testosterone replacement therapy among HIV-infected men in the CFAR Network of Integrated Clinical Systems.
Bhatia R; Murphy AB; Raper JL; Chamie G; Kitahata MM; Drozd DR; Mayer K; Napravnik S; Moore R; Achenbach C;
AIDS; 2015 Jan; 29(1):77-81. PubMed ID: 25387318
[TBL] [Abstract][Full Text] [Related]
16. Testosterone Replacement Therapy and Mortality in Older Men.
Hackett GI
Drug Saf; 2016 Feb; 39(2):117-30. PubMed ID: 26482385
[TBL] [Abstract][Full Text] [Related]
17. Association of Testosterone Replacement With Cardiovascular Outcomes Among Men With Androgen Deficiency.
Cheetham TC; An J; Jacobsen SJ; Niu F; Sidney S; Quesenberry CP; VanDenEeden SK
JAMA Intern Med; 2017 Apr; 177(4):491-499. PubMed ID: 28241244
[TBL] [Abstract][Full Text] [Related]
18. Testosterone replacement therapy can increase circulating endothelial progenitor cell number in men with late onset hypogonadism.
Liao CH; Wu YN; Lin FY; Tsai WK; Liu SP; Chiang HS
Andrology; 2013 Jul; 1(4):563-9. PubMed ID: 23653307
[TBL] [Abstract][Full Text] [Related]
19. Topical Testosterone Therapy Adherence and Outcomes Among Men With Primary or Secondary Hypogonadism.
Grabner M; Hepp Z; Raval A; Tian F; Khera M
J Sex Med; 2018 Feb; 15(2):148-158. PubMed ID: 29425664
[TBL] [Abstract][Full Text] [Related]
20. Factors that may be influencing the rise in prescription testosterone replacement therapy in adult men: a qualitative study.
Mascarenhas A; Khan S; Sayal R; Knowles S; Gomes T; Moore JE
Aging Male; 2016 Jun; 19(2):90-5. PubMed ID: 26927629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
